Dare Bioscience, Inc. (NASDAQ:DARE) Short Interest Up 142.1% in December

Dare Bioscience, Inc. (NASDAQ:DARE) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 466,123 shares, a growth of 142.1% from the November 30th total of 192,561 shares. Based on an average trading volume of 373,845 shares, the short-interest ratio is presently 1.2 days. Approximately 3.4% of the shares of the company are sold short. Approximately 3.4% of the shares of the company are sold short. Based on an average trading volume of 373,845 shares, the short-interest ratio is presently 1.2 days.

Dare Bioscience Price Performance

Shares of NASDAQ:DARE traded down $0.02 during trading on Friday, hitting $2.15. 90,121 shares of the company’s stock were exchanged, compared to its average volume of 297,061. The business’s 50-day simple moving average is $1.96 and its 200 day simple moving average is $2.19. The company has a market cap of $30.72 million, a price-to-earnings ratio of -1.15 and a beta of 0.77. Dare Bioscience has a 52-week low of $1.61 and a 52-week high of $9.19. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.18 and a quick ratio of 1.18.

Dare Bioscience (NASDAQ:DARE) last released its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.05. The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.01 million. As a group, equities analysts predict that Dare Bioscience will post -0.49 EPS for the current year.

Analysts Set New Price Targets

DARE has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dare Bioscience in a report on Wednesday, October 8th. Maxim Group raised Dare Bioscience from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a report on Thursday, September 4th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Dare Bioscience in a report on Tuesday, December 2nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

Hedge Funds Weigh In On Dare Bioscience

Institutional investors have recently bought and sold shares of the business. AMH Equity Ltd lifted its holdings in shares of Dare Bioscience by 20.0% in the 3rd quarter. AMH Equity Ltd now owns 232,373 shares of the biotechnology company’s stock valued at $488,000 after acquiring an additional 38,770 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Dare Bioscience during the 3rd quarter valued at approximately $37,000. Finally, Raymond James Financial Inc. lifted its position in Dare Bioscience by 810.6% in the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after buying an additional 13,650 shares during the last quarter. Institutional investors own 6.70% of the company’s stock.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.